Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open, Multicenter Phase III Clinical Study to Evaluate the Efficacy and Safety of Recombinant Human Coagulation Factor Ⅷ-Fc Fusion Protein (FRSW107) for Injection in Pediatric Patients With Severe Hemophilia A

NCT06136507 is registered in ClinicalTrials.gov with Hangzhou Gensciences Biopharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06136507
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06136507 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open, Multicenter Phase III Clinical Study to Evaluate the Efficacy and Safety of Recombinant Human Coagulation Factor Ⅷ-Fc Fusion Protein (FRSW107) for Injection in Pediatric Patients With Severe Hemophilia A
Lead sponsor
Hangzhou Gensciences Biopharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Not yet recruiting
Start date
December 25, 2026
Completion date
December 31, 2026
Enrollment
76 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

severe hemophilia a